Results 21 to 30 of about 38,022 (310)
BMJ Open Diabetes Research & Care, 2019 Introduction This real-world study compared glycemic effectiveness, treatment durability, and treatment costs with canagliflozin 300 mg versus any dose of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes mellitus (T2DM ...
Mukul Singhal +5 more
doaj +1 more source
The first successful desensitization protocol in exenatide allergy: a case report
Allergy, Asthma & Clinical Immunology, 2023 Background Glucagon-like peptide-1 (GLP-1) receptor agonists are important treatment options in obese patients with type 2 diabetes. To date, few immediate allergic reactions due to GLP-1 receptor agonists were reported.
Osman Ozan Yeğit +6 more
doaj +1 more source
Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists [PDF]
, 2017 Type 2 diabetes mellitus (T2DM) leads to bone fragility and predisposes to increased risk of fracture, poor bone healing and other skeletal complications.
Chantal Chenu +4 more
core +5 more sources
Pharmaceuticals, 2022 Tirzepatide is a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist and a promising therapy for type 2 diabetes mellitus (T2DM). GLP-1 is an incretin hormone with therapeutic potential beyond type
Ali Ismaeil +2 more
doaj +1 more source
Treatment of type 2 diabetes by free fatty acid receptor agonists [PDF]
, 2014 Dietary free fatty acids (FFAs), such as ω-3 fatty acids, regulate metabolic and anti-inflammatory processes, with many of these effects attributed to FFAs interacting with a family of G protein-coupled receptors.
Hudson, Brian D. +3 more
core +2 more sources
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects [PDF]
Frontiers in Endocrinology, 2021 Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists (GLP-1RAs) are widely used in the treatment of type 2 diabetes (T2DM) due to their attributes such as body weight loss, protection of islet β cells, promotion of islet β cell proliferation and minimal side effects.
Xin Zhao +8 more
openaire +3 more sources
The role of ECL2 in CGRP receptor activation: a combined modelling and experimental approach [PDF]
, 2013 The calcitonin gene-related peptide (CGRP) receptor is a complex of a calcitonin receptor-like receptor (CLR), which is a family B G-protein-coupled receptor (GPCR) and receptor activity modifying protein 1.
Alex C. Conner +13 more
core +2 more sources
Glucagon like Peptide-1(GLP-1) a Novel Therapeutic Strategy in Non-Alcoholic Fatty Liver Disease (NAFLD) [PDF]
Avicenna Journal of Medical Biochemistry, 2017 Non-alcoholic fatty liver disease (NAFLD) is a main cause of liver disease and its global prevalence is estimated to be 24%. At present no approved medicines are available for NAFLD treatment. Glucagon-like peptide-1 (GLP-1) is a significant regulator of
Ebrahim Abbasi Oshaghi
doaj +1 more source
Exenatide Improves Bone Quality in a Murine Model of Genetically Inherited Type 2 Diabetes Mellitus [PDF]
, 2017 Type 2 diabetes mellitus (T2DM) is associated with skeletal complications, including an increased risk of fractures. Reduced blood supply and bone strength may contribute to this skeletal fragility.
Andreozzi +64 more
core +6 more sources
GLP-1 Receptor Agonists and Kidney Protection
Medicina, 2019 Type 2 diabetes mellitus (T2DM) is the leading cause of chronic kidney disease (CKD). Diabetic nephropathy (DN) is determined by specific pathological structural and functional alterations of the kidneys in patients with diabetes, and its clinical manifestations are albuminuria and decline of glomerular filtration rate (GFR).
Eulalia Greco +5 more
openaire +3 more sources